Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Conflict thinking: Exploring the social basis of perceiving the world through the lens of social conflict.

Spruyt B, Van Droogenbroeck F, van Noord J.

Soc Sci Res. 2018 Aug;74:16-29. doi: 10.1016/j.ssresearch.2018.05.007. Epub 2018 May 29.

PMID:
29961482
2.

Long term survival after admission for COPD exacerbation: A comparison with the general population.

van Hirtum PV, Sprooten RTM, van Noord JA, van Vliet M, de Kruif MD.

Respir Med. 2018 Apr;137:77-82. doi: 10.1016/j.rmed.2018.02.015. Epub 2018 Feb 24.

PMID:
29605217
3.

In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers.

Horhota ST, van Noord JA, Verkleij CB, Bour LJ, Sharma A, Trunk M, Cornelissen PJ.

AAPS J. 2015 Jul;17(4):871-80. doi: 10.1208/s12248-015-9751-7. Epub 2015 Mar 21.

4.

Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease.

Hohlfeld JM, Sharma A, van Noord JA, Cornelissen PJ, Derom E, Towse L, Peterkin V, Disse B.

J Clin Pharmacol. 2014 Apr;54(4):405-14. doi: 10.1002/jcph.215. Epub 2013 Nov 27.

5.

Flyingfish feeding ecology in the eastern Pacific: prey partitioning within a speciose epipelagic community.

Van Noord JE, Lewallen EA, Pitman RL.

J Fish Biol. 2013 Aug;83(2):326-42. doi: 10.1111/jfb.12173. Epub 2013 Jul 9.

PMID:
23902309
6.

Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination.

Barnes N, van Noord JA, Brindicci C, Lindemann L, Varoli G, Perpiña M, Guastalla D, Casula D, Patel S, Chanez P; FACTO (Foster® As Complete Treatment Option) Study Group.

Pulm Pharmacol Ther. 2013 Oct;26(5):555-61. doi: 10.1016/j.pupt.2013.01.011. Epub 2013 Mar 22.

PMID:
23524015
7.

Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial.

Bodzenta-Lukaszyk A, van Noord J, Schröder-Babo W, McAulay K, McIver T.

Curr Med Res Opin. 2013 May;29(5):579-88. doi: 10.1185/03007995.2013.772506. Epub 2013 Feb 20.

PMID:
23368897
8.

Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease.

van den Berge M, Hop WC, van der Molen T, van Noord JA, Creemers JP, Schreurs AJ, Wouters EF, Postma DS; COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) study group.

Respir Res. 2012 Jun 6;13:44. doi: 10.1186/1465-9921-13-44.

9.

Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.

Beier J, van Noord J, Deans A, Brooks J, Maden C, Baggen S, Mehta R, Cahn A.

Int J Chron Obstruct Pulmon Dis. 2012;7:153-64. doi: 10.2147/COPD.S26100. Epub 2012 Mar 5.

10.

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.

D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T.

Respir Res. 2011 Dec 7;12:156. doi: 10.1186/1465-9921-12-156.

11.

24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD.

van Noord JA, Smeets JJ, Drenth BM, Rascher J, Pivovarova A, Hamilton AL, Cornelissen PJ.

Pulm Pharmacol Ther. 2011 Dec;24(6):666-72. doi: 10.1016/j.pupt.2011.07.006. Epub 2011 Aug 6.

PMID:
21839850
12.

Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial.

Kerstjens HA, Disse B, Schröder-Babo W, Bantje TA, Gahlemann M, Sigmund R, Engel M, van Noord JA.

J Allergy Clin Immunol. 2011 Aug;128(2):308-14. doi: 10.1016/j.jaci.2011.04.039. Epub 2011 Jun 2.

PMID:
21636120
13.

QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.

van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, Overend T.

Thorax. 2010 Dec;65(12):1086-91. doi: 10.1136/thx.2010.139113. Epub 2010 Oct 26.

PMID:
20978028
14.

Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms.

van Noord JA, Aumann JL, Janssens E, Smeets JJ, Zaagsma J, Mueller A, Cornelissen PJ.

Respir Med. 2010 Jul;104(7):995-1004. doi: 10.1016/j.rmed.2010.02.017. Epub 2010 Mar 29.

15.

The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.

van Noord JA, Cornelissen PJ, Aumann JL, Platz J, Mueller A, Fogarty C.

Respir Med. 2009 Jan;103(1):22-9. doi: 10.1016/j.rmed.2008.10.002. Epub 2008 Nov 20.

16.

Improvements with tiotropium in COPD patients with concomitant asthma.

Magnussen H, Bugnas B, van Noord J, Schmidt P, Gerken F, Kesten S.

Respir Med. 2008 Jan;102(1):50-6. Epub 2007 Oct 24.

17.

Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.

van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ.

Chest. 2006 Mar;129(3):509-17.

PMID:
16537846
18.

Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.

van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ.

Eur Respir J. 2005 Aug;26(2):214-22.

19.

Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.

Dahl R, Creemers JP, Van Noord J, Sips A, Della Cioppa G, Thomson M, Andriano K, Kottakis J, Fashola T.

Respiration. 2004 Mar-Apr;71(2):126-33.

PMID:
15031566
20.

One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.

Oostenbrink JB, Rutten-van Mölken MP, Al MJ, Van Noord JA, Vincken W.

Eur Respir J. 2004 Feb;23(2):241-9.

21.

Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease.

Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S.

Thorax. 2003 Oct;58(10):855-60.

22.

Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic Bronchitis.

Solèr M, Lode H, Baldwin R, Levine JH, Schreurs AJ, van Noord JA, Maesen FP, Zehrer M; European Gatifloxacin Study group.

Eur J Clin Microbiol Infect Dis. 2003 Mar;22(3):144-50. Epub 2003 Mar 5.

PMID:
12649711
23.

Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma.

Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, Konstantopoulos S, Rojas R, van Noord JA, Pons M, Gilles L, Leff JA; Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group.

Thorax. 2003 Mar;58(3):211-6.

24.

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol.

Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ Jr, Kesten S, Towse L.

Chest. 2002 Jul;122(1):47-55.

PMID:
12114338
25.

Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease.

van Noord JA, Smeets JJ, Custers FL, Korducki L, Cornelissen PJ.

Eur Respir J. 2002 Apr;19(4):639-44.

26.

Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.

Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ; Dutch/Belgian Tiotropium Study Group.

Eur Respir J. 2002 Feb;19(2):209-16.

27.
28.

Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium.

van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM.

Eur Respir J. 2000 May;15(5):878-85.

29.
31.

Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group.

Villaran C, O'Neill SJ, Helbling A, van Noord JA, Lee TH, Chuchalin AG, Langley SJ, Gunawardena KA, Suskovic S, Laurenzi M, Jasan J, Menten J, Leff JA.

J Allergy Clin Immunol. 1999 Sep;104(3 Pt 1):547-53.

PMID:
10482826
32.
33.
34.

Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer.

Sulzer MA, Leers MP, van Noord JA, Bollen EC, Theunissen PH.

Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1319-23.

PMID:
9563756
35.

Chronic bronchopleural fistula in conservatively-treated calcified fibrothorax.

Sulzer MA, van Noord JA.

Monaldi Arch Chest Dis. 1997 Jun;52(3):229-31.

PMID:
9270247
36.

Pulmonary sarcoid-like granulomata in a patient treated for extrapulmonary Hodgkin's disease.

van den Berg, Fickers M, Theunissen P, van Noord JA.

Respiration. 1997;64(1):114-7.

PMID:
9044487
37.

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action.

van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP.

Eur Respir J. 1996 Aug;9(8):1684-8.

38.

[Opportunistic lung infections in patients with chronic obstructive pulmonary disease; a side effect of inhalation corticosteroids?].

Sulzer MA, van Noord JA.

Ned Tijdschr Geneeskd. 1996 May 11;140(19):1041. Dutch. No abstract available.

PMID:
8684499
39.

[Indications for an increase in lung disease caused by Mycobacterium kansasii in the former Limburg mining area?].

Cerdá de Palou E, Sulzer MA, van Noord JA.

Ned Tijdschr Geneeskd. 1995 Jun 17;139(24):1231-6. Dutch.

PMID:
7791934
40.

Effect of zatebradine, a novel 'sinus node inhibitor', on pulmonary function compared to placebo.

Maesen FP, Smeets JJ, van Noord JA, Nehmiz G, Wald FD, Cornelissen PJ.

Pulm Pharmacol. 1994 Dec;7(6):349-55.

PMID:
7549222
41.

Assessment of reversibility of airflow obstruction.

Van Noord JA, Smeets J, Clément J, Van de Woestijne KP, Demedts M.

Am J Respir Crit Care Med. 1994 Aug;150(2):551-4.

PMID:
8049845
42.

Small cell lung cancer with paraneoplastic nephrotic syndrome.

Boon ES, Vrij AA, Nieuwhof C, van Noord JA, Zeppenfeldt E.

Eur Respir J. 1994 Jun;7(6):1192-3.

43.

A large air-filled cyst in a patient with migratory infiltrates.

Linsen VM, van Noord JA.

Chest. 1994 Jan;105(1):253-4. No abstract available.

PMID:
8275742
44.

Clinical significance of intranodal and extranodal growth in lymph node metastases of non-small cell lung cancer.

Bollen EC, Theunissen PH, van Duin CJ, Drenth BM, van Noord JA, Blijham GH.

Scand J Thorac Cardiovasc Surg. 1994;28(3-4):97-102.

PMID:
7792562
46.

Tumor embolus in lung surgery. A case report and review of the literature.

Bollen EC, Van Duin CJ, Van Noord JA, Janssen JG, Theunissen PH.

Eur J Cardiothorac Surg. 1993;7(2):104-6. Review.

PMID:
8442977
47.

Total respiratory resistance and reactance in ankylosing spondylitis and kyphoscoliosis.

van Noord JA, Cauberghs M, Van de Woestijne KP, Demedts M.

Eur Respir J. 1991 Sep;4(8):945-51.

PMID:
1783085
48.

Total respiratory resistance and reactance in patients with asthma, chronic bronchitis, and emphysema.

Van Noord JA, Clément J, Van de Woestijne KP, Demedts M.

Am Rev Respir Dis. 1991 May;143(5 Pt 1):922-7.

PMID:
2024844
49.

Clinical applications of forced oscillation technique.

Demedts M, Van Noord JA, Van De Woestijne KP.

Chest. 1991 Apr;99(4):795-7. No abstract available.

PMID:
2009776
50.

Clinical applications and modelling of forced oscillation mechanics of the respiratory system.

Van Noord JA, Van de Woestijne KP, Demedts M.

Eur Respir J. 1991 Feb;4(2):247-8. No abstract available.

PMID:
2044744

Supplemental Content

Loading ...
Support Center